(VIANEWS) – The Market ended the session with PCI BIOTECH HOLD (PCIB.OL) jumping 17.49% to kr2.15 on Tuesday while Oslo Børs Benchmark Index_GI slid 0.72% to kr1,299.63.
PCI BIOTECH HOLD’s last close was kr1.83, 69.14% below its 52-week high of kr5.93.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.
Volume
Today’s last reported volume for PCI BIOTECH HOLD is 1770110 which is 158.05% above its average volume of 685957.
Yearly Top and Bottom Value
PCI BIOTECH HOLD’s stock is valued at kr2.15 at 21:34 EST, way under its 52-week high of kr5.93 and way higher than its 52-week low of kr1.20.
More news about PCI BIOTECH HOLD (PCIB.OL).
